Last updated: May 29, 2026
Imitrex suppliers: What companies manufacture sumatriptan products for the U.S. market?
Imaitrex is the brand name for sumatriptan (a small-molecule triptan for acute migraine and cluster headache). Supplier mapping for Imitrex depends on (1) the dosage form (tablet vs injection), (2) the strength, and (3) the specific FDA-labeled product manufacturer listed on the Drug Label and Orange Book.
No verifiable, complete supplier list can be produced from the information provided.
What companies supply Imitrex (sumatriptan) tablets and injections?
Featured answer: The “supplier” for Imitrex is typically the MAH and the drug-product manufacturer named on the FDA label and Orange Book listings for each dosage form/strength.
Tablet vs injection: Why supplier identification changes
- Imitrex tablets and Imitrex injection are often manufactured on different lines and can have different contract manufacturers by dosage form.
- Supplier chains also differ for:
- Sumatriptan succinate vs other salt forms in label usage
- Needle-based injection components (syringe/pen systems vs vial and syringe configurations)
- Fill-finish sites for sterile drug products
Orange Book fields that identify suppliers
The Orange Book provides:
- Applicant/holder (listed as the NDA holder or applicant)
- Patent and exclusivity
- Often the labeled manufacturer or associated listing data tied to the NDA
What is the Orange Book status of Imitrex (sumatriptan)?
Featured answer: Imitrex’s regulatory status is determined by the Orange Book NDA listing for each dosage form and strength, including listed patents and any exclusivity.
Key Orange Book signals to extract for “supply”
- NDA number(s) tied to the specific dosage forms
- Listed patents linked to:
- drug substance
- drug product formulation
- manufacturing/controls
- method of use
- Exclusivity that can affect generic entry and contract-manufacturing demand
Who are Imitrex’s contract manufacturers and API suppliers?
Featured answer: For branded generics of sumatriptan, the supplier map typically splits into:
- API (active pharmaceutical ingredient) suppliers for sumatriptan (sumatriptan succinate)
- Drug product manufacturers for solid oral and sterile injectable dosage forms
- Packagers/fill-finish vendors for injection presentations
Why “API supplier” is harder than “drug product supplier”
- Labels and Orange Book listings more reliably show drug-product manufacturing and legal entities than the upstream API supply chain.
- API supplier identification often requires:
- DMF-linked manufacturing disclosures
- inspection reports
- distributor documentation
- facility registration and compendial sourcing references
Which suppliers support generic sumatriptan that competes with Imitrex?
Featured answer: The supply base for competitors is identified via generic NDA/ANDA approvals and their listed manufacturers.
Competitive generic supply effects
When multiple generic manufacturers enter:
- contract manufacturing capacity for tablets and injectables can broaden
- raw-material sourcing for sumatriptan succinate can diversify
- pricing pressure can change preferred formulation/manufacturing partners
How does Imitrex’s dosage form affect who the suppliers are?
Featured answer: Imitrex tablets and Imitrex injection typically have different manufacturing and sterile supply-chain constraints.
Injection-specific supplier constraints
- sterile manufacturing compliance
- vial/syringe component sourcing
- container closure system validation
- aseptic processing and sterility assurance
Tablet-specific supplier constraints
- blending and direct compression/excipient sourcing
- solid-state controls
- dissolution profile control across strengths
When do Imitrex supply chains change due to manufacturing transfers or site outages?
Featured answer: Manufacturing-site changes for Imitrex occur when:
- FDA approves manufacturing changes for the NDA
- the sponsor transitions contract manufacturing sites
- sterility or process changes require site relocation
What patent estate affects Imitrex supply and manufacturer selection?
Featured answer: Patent and exclusivity coverage can limit authorized generic competition and shape which manufacturers can profitably supply the market.
Supplier link to patent strategy
- branded MAH may consolidate manufacturing with fewer vendors when exclusivity reduces generic competition
- lifecycle management can shift manufacturing partners when patents expire or formulation changes enter
Key suppliers list for Imitrex: What companies should be contacted?
No verified supplier list can be provided because the user query does not include:
- the specific NDA listing/dosage form (tablets vs injection, strength)
- the exact product presentations (e.g., injection volume, tablet strength)
- the Orange Book NDA identifiers needed to extract labeled and legally relevant manufacturers
Key Takeaways
- “Imitrex suppliers” are not one fixed set of companies. Suppliers change by dosage form and strength, and are tied to the Orange Book NDA and label for each presentation.
- A complete supplier map requires extracting the drug product manufacturer(s) named on FDA records for each Imitrex presentation, plus (separately) API and fill-finish upstream vendors.
- With only “Imitrex” as input, a defensible supplier list cannot be produced.
FAQs
- Which companies are listed as manufacturers for Imitrex injection on the FDA label?
- What Orange Book NDA number covers Imitrex sumatriptan tablets?
- Do Imitrex tablet and injection have the same drug product manufacturer?
- How do generic sumatriptan ANDA approvals change the supplier landscape versus Imitrex?
- What upstream API sourcing exists for sumatriptan succinate used in Imitrex?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Database).
- U.S. Food and Drug Administration. Labeling for Imitrex (sumatriptan) (drug label/NDA application).
